Integration of new or experimental treatment options and new approaches to clinical trials

被引:3
作者
Quinn, M
Pfisterer, J
Avall-Lundqvist, E
Bookman, M
Bowtell, D
Casado, A
Cervantes, A
Grenman, S
Harper, P
Oza, A
Pecorelli, S
Pujade-Lauraine, E
Trimble, E
Vasey, P
Wagner, U
机构
关键词
D O I
10.1093/annonc/mdi964
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:30 / 35
页数:6
相关论文
共 27 条
[1]  
Berek JS, 2003, J Clin Oncol, V21, p168s, DOI DOI 10.1200/JCO.2003.01.517
[2]   Systemic treatment policies in ovarian cancer: the next 10 years [J].
Biagi, JJ ;
Eisenhauer, EA .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 :231-240
[3]  
Bookman M, 2001, CLIN CANCER RES, V7, p3756S
[4]  
CAMPOS SM, 2004, P AM SOC CLIN RES, V22
[5]   Immunological treatment of ovarian cancer [J].
Cannon, MJ ;
Santin, AD ;
O'Brien, TJ .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2004, 16 (01) :87-92
[6]  
Cure H, 2001, P AN M AM SOC CLIN, V20, p204a
[7]   Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian trials in ovarian cancer (MITO-1) randomized study [J].
De Placido, S ;
Scambia, G ;
Di Vagno, G ;
Naglieri, E ;
Lombardi, AV ;
Biamonte, R ;
Marinaccio, M ;
Carteni, G ;
Manzione, L ;
Febbraro, A ;
de Matteis, A ;
Gasparini, G ;
Valerio, MR ;
Danese, S ;
Perrone, F ;
Lauria, R ;
De Laurentiis, M ;
Greggi, S ;
Gallo, C ;
Pignata, S .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2635-2642
[8]   A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer [J].
du Bois, A ;
Lück, HJ ;
Meier, W ;
Adams, HP ;
Möbus, V ;
Costa, S ;
Bauknecht, T ;
Richter, B ;
Warm, M ;
Schröder, W ;
Olbricht, S ;
Nitz, U ;
Jackisch, C ;
Emons, G ;
Wagner, U ;
Kuhn, W ;
Pfisterer, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17) :1320-1330
[9]  
EHLEN T, 2002, P AN M AM SOC CLIN, V21, pA9
[10]  
FINKLER N, 2001, P AM SOC CLIN ONCOL, V20